446 related articles for article (PubMed ID: 11389070)
1. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
Hiraga T; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
[TBL] [Abstract][Full Text] [Related]
2. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs.
Michigami T; Hiraga T; Williams PJ; Niewolna M; Nishimura R; Mundy GR; Yoneda T
Breast Cancer Res Treat; 2002 Oct; 75(3):249-58. PubMed ID: 12353814
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
Yoneda T; Sasaki A; Dunstan C; Williams PJ; Bauss F; De Clerck YA; Mundy GR
J Clin Invest; 1997 May; 99(10):2509-17. PubMed ID: 9153295
[TBL] [Abstract][Full Text] [Related]
4. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma.
Yoneda T; Michigami T; Yi B; Williams PJ; Niewolna M; Hiraga T
Cancer; 2000 Jun; 88(12 Suppl):2979-88. PubMed ID: 10898341
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
Sasaki A; Boyce BF; Story B; Wright KR; Chapman M; Boyce R; Mundy GR; Yoneda T
Cancer Res; 1995 Aug; 55(16):3551-7. PubMed ID: 7627963
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.
Zheng Y; Zhou H; Brennan K; Blair JM; Modzelewski JR; Seibel MJ; Dunstan CR
Bone; 2007 Feb; 40(2):471-8. PubMed ID: 17092788
[TBL] [Abstract][Full Text] [Related]
7. Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
Ebert R; Meissner-Weigl J; Zeck S; Määttä J; Auriola S; Coimbra de Sousa S; Mentrup B; Graser S; Rachner TD; Hofbauer LC; Jakob F
Mol Cancer; 2014 Dec; 13():265. PubMed ID: 25496233
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
[TBL] [Abstract][Full Text] [Related]
9. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.
Hiraga T; Ueda A; Tamura D; Hata K; Ikeda F; Williams PJ; Yoneda T
Int J Cancer; 2003 Oct; 106(6):973-9. PubMed ID: 12918079
[TBL] [Abstract][Full Text] [Related]
10. Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells.
Journé F; Kheddoumi N; Chaboteaux C; Duvillier H; Laurent G; Body JJ
Breast Cancer Res; 2008; 10(1):R4. PubMed ID: 18190680
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
[TBL] [Abstract][Full Text] [Related]
12. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone.
Magnetto S; Boissier S; Delmas PD; Clezardin P
Int J Cancer; 1999 Oct; 83(2):263-9. PubMed ID: 10471537
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer.
Hiraga T; Myoui A; Choi ME; Yoshikawa H; Yoneda T
Cancer Res; 2006 Feb; 66(4):2067-73. PubMed ID: 16489006
[TBL] [Abstract][Full Text] [Related]
14. Wenshen Zhuanggu formula effectively suppresses breast cancer bone metastases in a mouse Xenograft model.
Li JJ; Chen WL; Wang JY; Hu QW; Sun ZP; Zhang S; Liu S; Han XH
Acta Pharmacol Sin; 2017 Oct; 38(10):1369-1380. PubMed ID: 28414206
[TBL] [Abstract][Full Text] [Related]
15. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model.
Mbalaviele G; Dunstan CR; Sasaki A; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 1996 Sep; 56(17):4063-70. PubMed ID: 8752180
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of bisphosphonates.
Green JR
Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
Hussein O; Tiedemann K; Komarova SV
Bone; 2011 Feb; 48(2):202-11. PubMed ID: 20849994
[TBL] [Abstract][Full Text] [Related]
18. Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells.
Nakata A; Tsujimura T; Sugihara A; Okamura H; Iwasaki T; Shinkai K; Iwata N; Kakishita E; Akedo H; Terada N
Anticancer Res; 1999; 19(5B):4131-8. PubMed ID: 10628364
[TBL] [Abstract][Full Text] [Related]
19. Ipriflavone inhibits osteolytic bone metastasis of human breast cancer cells in a nude mouse model.
Iwasaki T; Mukai M; Tsujimura T; Tatsuta M; Nakamura H; Terada N; Akedo H
Int J Cancer; 2002 Aug; 100(4):381-7. PubMed ID: 12115517
[TBL] [Abstract][Full Text] [Related]
20. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice.
Sasaki A; Kitamura K; Alcalde RE; Tanaka T; Suzuki A; Etoh Y; Matsumura T
Int J Cancer; 1998 Jul; 77(2):279-85. PubMed ID: 9650565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
